Abstract
ECP is an established therapy for CTCL yet patterns of utilization, complication rates, and outcomes vary widely among treatment centers. We hereby report our experience with 13 patients (pts) treated with ECP from 2013-2019; median age was 65 (range 47-87) years. All pts had advanced stage CTCL; 8 (61.5%) with mycosis fungoides (MF) and 5 (38.5%) with Sezary syndrome (SS). Median time from diagnosis to pheresis start was 2.8 months with a median of 2 lines of prior therapy. All pts initially started on a ECP regimen of 2 consecutive days per week with 8 (61.5%) pts concurrently using oral bexarotene (Bex) and subcutaneous interferon alpha (IFN), 2 pts on ECP alone (15.4%), 2 (15.4%) with Bex only, and 1 (7.7%) with IFN only.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
